Treating the Root Cause of Your Swelling

Because Acquired Angioedema with C1 Inhibitor Deficiency (AAE-C1-INH) is frequently a secondary symptom of an underlying blood or immune disorder, the most effective long-term strategy for managing it is to treat the “root cause” ^[1][2].

While acute medications stop a single attack, treating the underlying condition aims for clinical remission—a state where the attacks stop happening entirely or become significantly less frequent ^[3][4].

Addressing the B-Cell “Clone”

In most patients, the deficiency of C1-INH is caused by an abnormal group of white blood cells (a “clone”), such as in MGUS (Monoclonal Gammopathy of Undetermined Significance) or certain types of B-cell lymphoma ^[5][4]. These cells are responsible for producing the proteins or antibodies that destroy your C1 inhibitor ^[1].

The Role of Rituximab

Rituximab is a monoclonal antibody that specifically targets and eliminates B-cells. It has become a specialist-directed option of treatment for AAE-C1-INH ^[3]. This is an off-label use for AAE. It carries material risks including infusion reactions, serious infection, hepatitis B reactivation, hypogammaglobulinemia, and impaired vaccine responses.

• Achieving Remission: In one multicenter study, 34 out of 51 patients (66%) achieved clinical remission after treatment that included rituximab. This is observational cohort evidence, not a guaranteed individual response ^[3].
• Targeted Use: For patients with MGUS, rituximab may be used specifically to stop recurrent, severe angioedema attacks, even if the MGUS itself wouldn’t normally require treatment ^[4][5].
• Combination Therapy: If an overt lymphoma is present, rituximab is often combined with traditional chemotherapy (such as the R-CHOP or rituximab-bendamustine regimens) ^[6][4]. Research suggests that combining rituximab with chemotherapy may lead to fewer relapses of the angioedema compared to using rituximab alone ^[3].

Can AAE-C1-INH Be “Cured”?

The goal of treating the underlying cause is to achieve a durable remission. However, it is important to have realistic expectations:

• Lymphoma vs. MGUS: Remission rates can vary. In some cohorts, all patients treated for Splenic Marginal Zone Lymphoma saw their angioedema disappear ^[5]. For those with MGUS, about 35% achieved complete clinical remission in a long-term follow-up study ^[4].
• Autoantibody Impact: If you have anti-C1-INH autoantibodies, it may be slightly more difficult to achieve long-term remission, though it is still possible with the right treatment plan ^[3][5].
• Recurrence: Because the underlying B-cell disorder can sometimes return, a return of swelling can be an early signal that the underlying disease is relapsing and needs further attention. However, recurrent swelling does not automatically prove a hematologic relapse ^[7][8].

Watching Your Lab Results Normalize

One of the most encouraging signs that treatment is working is the normalization of complement levels in your blood work ^[7].

As the treatment eliminates the abnormal B-cells:

1. C4 and C1q levels typically begin to rise back toward the normal range as they are no longer being “consumed” by the immune reaction ^[7][8].
2. C1-INH function often improves, though it may not always reach perfectly normal levels even if the swelling stops ^[9][10].
3. Monoclonal Protein: In cases related to MGUS, achieving clinical remission is highly correlated with the abnormal “monoclonal protein” becoming undetectable in your blood. However, MGUS commonly persists and is not ordinarily treated just to make the protein disappear ^[4].

Your doctors will use these blood tests to “track” your progress. If your numbers improve and your swelling stops, you may eventually be able to reduce or stop your daily preventive (prophylactic) medications, though you will still need lifelong monitoring to ensure the condition remains in check ^[4][8].